Actuate Therapeutics

CEO Daniel M. Schmitt has led the company since before its 2024 IPO; COO Andrew P.

Mazar and CFO Paul Lytle bring development and financing experience; industry veteran Martin Huber, MD joined the board in May 2026. Nevertheless, the team has not yet commercialized a product at Actuate, stock‑based compensation is material, and execution risk remains high.

Major holder BIOS/Bios Equity Partners owns a significant stake, aligning some incentives but also concentrating control.